Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions

References

• Fisher B, Foster R, Gardner B et al. Relation of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52, 1551–1557 (1983).
   PubMed Web of Science ®Google Scholar
• Fornier M, Munster P, Seidman A. Update on the management of advanced breast cancer. Oncology 13, 647–658 (1999).
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. (EBCTCG). Lancet365,1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1, 2000. J. Natl Cancer Inst. Monogr. 93, 979–989 (2001).
   Google Scholar
• Goldhirsch A, Glick, JH, Gelber RD et al. Meeting highlights: international consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 16, 1569–1583 (2005).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Falkson C, Campos D et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first line therapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J. Clin. Oncol. 21, 968–975 (2003).
   PubMed Web of Science ®Google Scholar
• Jassem J, Pienkowski T, Pluzanska A et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized Phase III multicenter trial. J. Clin. Oncol. 19, 1707–1715 (2001).
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976–983 (2003).
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Bryant J, Lembersky BC et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28. J. Clin. Oncol. 23, 3686–3696 (2005).
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Singletary SE, Valero V et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin. Cancer Res. 8, 1073–1079 (2002).
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Albain KS, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 143).
   Google Scholar
• Hudis C, Citron M, Berry D et al. Five year follow-up of INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res. Treat. 89 (2005) (Abstract 49).
   Google Scholar
• Citron ML, Berry DA, Cirrincione C et al. Dose-dense (DD) AC followed by paclitaxel is associated with more frequent moderate anemia compared to sequential (s) and/or less DD treatment: update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, and NCCTG. Proc. Am. Soc. Clin. Oncol. 24, 33S (2005) (Abstract 620).
   Google Scholar
• Berry DA, Cirrincione C, Henderson IC et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen receptor negative, node-positive breast cancer: 20-year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res. Treat. 88(Suppl. 1), S17 (2004) (Abstract 29).
   Google Scholar
• Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352, 2302–2313 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, O’Neill A, Sparano JA et al. E2197: Phase III of AT vs AC in the adjuvant treatment of node-positive and high-risk node-negative breast cancer. Proc. Am. Soc. Clin. Oncol. 24 (2005) (Abstract 512).
   Google Scholar
• Roche H, Fumoleau P, Spielmann M et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC 100 vs 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node-positive breast cancer. Breast Cancer Res. Treat. 88 (2004) (Abstract 27).
   Google Scholar
• Bear HD, Anderson S, Smith RE et al. A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) and to preoperative AC followed by postoperative T in patients with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res. Treat. 88, S16 (2004) (Abstract 26).
   Google Scholar
• Heys SD, Hutcheon AW, Sarkar TK et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin. Breast Cancer 3(Suppl. 2), S69–S74 (2002).
   PubMedGoogle Scholar
• Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl Cancer Inst. Monogr. 30, 96–102 (2001).
   PubMedGoogle Scholar
• Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once very 3 weeks. J. Clin. Oncol. 23, 5983–5992 (2005).
   PubMed Web of Science ®Google Scholar
• Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: Phase II study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc. Am. Soc. Clin. Oncol. 23, 6S (2004) (Abstract 512).
   Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Davidson N et al. NCCTG 9831: May 2005 update. Proc. Am. Soc. Clin. Oncol. (2005) (Oral presentation).
   Google Scholar
• Slamon D, Eiermann W, Robert N et al. Phase III trial comparing AC-T with AC-TH with TCH in the adjuvant treatment of HER2 positive breast cancer patients: first interim efficacy analysis. Breast Cancer Res. Treat. 89 (2005) (Abstract 1).
   Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Trudeau ME. Optimizing adjuvant breast cancer chemotherapy: rationale for MA.21 study. Oncology 15, 7–13 (2001).
   PubMedGoogle Scholar
• Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794–7803 (2005).
   PubMed Web of Science ®Google Scholar
• Dang C, Smith K, Lake D et al. Preliminary cardiac safety result of dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer. Breast Cancer Res. Treat. 89 (2005) (Abstract 2041).
   Google Scholar
• Miller K, Wang M, Gralaw J et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res. Treat. 89 (2005) (Abstract 3).
   Google Scholar